Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism

NCT01759888 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: 18F-DTBZ

Sponsor

Chang Gung Memorial Hospital

Collaborators

[object Object]